secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytoDyn Inc. (CYDY)
CIK:        0001175680
Form:       8-K
Filed at:   2023-11-28T23:59:59+00:00
Accession:  0001558370-23-019363
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Samsung BioLogics terminates MSA with CytoDyn effective Jan 5, 2024; company has sufficient leronlimab for trials
--------------------------------------------------------------------------------

- Samsung informed CytoDyn on Nov 21, 2023 of intent to terminate MSA effective Jan 5, 2024.
- Agreement from April 2019 covered tech transfer, manufacturing, vial filling, and supply for leronlimab.
- Samsung paused manufacturing for all unfulfilled commitments in January 2022.
- CytoDyn states it holds sufficient leronlimab for short-term prospective clinical trials.
- Company plans to continue resolving outstanding issues including breach notice, payment schedule, and extended manufacturing postponement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175680/000155837023019363/0001558370-23-019363-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175680/000155837023019363/cydy-20231121x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-019363

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer